Results 21 to 30 of about 79,111 (213)

Effect of long-term therapy with AT1angiotensin II receptor blockers in combination with aldosterone receptor inhibitor on ischemic myocardial remodelling and chronic heart failure

Медицинский совет, 2014
The article presents the results of a 6-month long-term therapy with angiotensin II receptor blocker Valsacor and aldosterone receptor blocker Spironolactone in patients with chronic heart failure (CHF) against a background of ischemic and/or post ...
AT Teplyakov, EV Grakova, AV Andrianova, EY Pushnikova, NV Protopopova, RS Karpov   +5 more
doaj   +1 more source

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Methylglyoxal Augments Angiotensin II–Induced Contraction in Rat Isolated Carotid Artery

Journal of Pharmacological Sciences, 2010
.: Methylglyoxal (MGO), a metabolite of glucose, accumulates in vascular tissues of a hypertensive animal. In the present study, we examined the effect of MGO on angiotensin (Ang) II–induced contraction of rat carotid artery.
Masashi Mukohda, Hideyuki Yamawaki, Muneyoshi Okada, Yukio Hara   +3 more
doaj   +1 more source

Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function [PDF]

, 2014
<b>Objective:</b><p></p> Mitochondria-derived reactive oxygen species (ROS) play important roles in the development of cardiovascular disease highlighting the need for novel targeted therapies.
Adlam, Cai, Calhoun, Chacko, Chandran, DAgostino, Dai, Dai, Dikalova, Doughan, Evans, Flores-Munoz, Flores-Munoz, Gane, Graham, Graham, Gutierrez, Halliwell, Jalil, Jeffs, Landmesser, London, Lowes, Mercer, Messerli, Murphy, Murphy, Nakagami, Nakamura, Nozoe, Qin, Rajagopalan, Roman, Ross, Snow, Watkins, Winterbourn, Yang, Yasunari, Zhang, Zhang, Zorov   +41 more
core   +1 more source

Circumscribed ciliochoroidal effusion presenting as an acute angle closure attack

Journal of Ophthalmic & Vision Research, 2017
Purpose: To report a case of choroidal effusion probably caused by angiotensin receptor II blocker. Case Report: A 52-year-old man with aplastic anemia and high blood pressure who developed unilateral acute angle closure glaucoma after receiving oral ...
Roslyn Kathryn Manrique Lipa, María Eugenia González Sánchez, Carlos Antonio Hijar Ordovas, Abel Rojo Aragües, Carmen Garcia Borque   +4 more
doaj   +1 more source

Intoxication with massive doses of amlodipine and candesartan requiring venoarterial extracorporeal membrane oxygenation

Acute Medicine & Surgery, 2023
Background Calcium channel blockers and angiotensin II receptor blockers are commonly prescribed to treat hypertension. Massive overdoses can cause both distributive and cardiogenic shock because of their effects on vascular smooth muscles and severe ...
Minagawa Yusuke, Yamana Hidetoshi, Tsutsumi Yusuke, Ishigami Koji, Togo Masahito, Yasuda Susumu, Ogura Takayuki   +6 more
doaj   +1 more source

A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure [PDF]

, 2019
Aims Heart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused by a primary disease of the myocardium (cardiomyopathy).
Anker, Stefan D., Cleland, John G. F., Dickstein, Kenneth, Hillege, Hans L., Lam, Carolyn S. P., Lang, Chim C., Metra, Marco, Nauta, Jan F., Ng, Leong L., Romaine, Simon P. R., Sama, Iziah E., Samani, Nilesh J., Ter Maaten, Jozine M., Tromp, Jasper, van der Meer, Peter, van Veldhuisen, Dirk J., Voors, Adriaan A., Woolley, Rebecca J., Zannad, Faiez   +18 more
core   +5 more sources

Concentration-Dependent Inhibitory Effect of Irbesartan on Renal Uric Acid Transporters

Journal of Pharmacological Sciences, 2010
Hyperuricemia is currently recognized as a risk factor for cardiovascular diseases. It has been reported that the angiotensin II–receptor blocker (ARB) losartan decreases serum uric acid level.
Makiko Nakamura, Naohiko Anzai, Promsuk Jutabha, Hiroyuki Sato, Hiroyuki Sakurai, Kimiyoshi Ichida   +5 more
doaj   +1 more source

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala, Akshay S Desai, Jean L. Rouleau, Jianjian Gong, John J. V. McMurray, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, Milton Packer, null null, Scott D. Solomon, Victor C. Shi   +11 more
core   +3 more sources

Drug treatment of hypertension: focus on vascular health [PDF]

, 2016
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C., Lang, Ninian N., Touyz, Rhian M.   +2 more
core   +1 more source